Kava
[Download PDF]
Piper methysticum G. Forst.
[Fam. Piperaceae]
Overview
Kava is traditionally served as a beverage in social or
ceremonial rituals in island communities of the South Pacific (e.g., Fiji, Vanuatu,
Samoa, Tonga), where it is revered as the
primary cultural and medicinal botanical (Lebot et al., 1992; Singh, 1992; Singh and Blumenthal, 1997). Its uses
were first described in detail by botanist J.G. Forster on the voyage of Captain James Cook in the late 1700s
(Forster, 1777). Kava beverage is used as a symbol of welcome and respect to
visiting heads of state and other dignitaries (Singh and Blumenthal, 1997).
Kava use has been popular as a phytomedicine in Europe for decades; it was approved in 1990 as a
nonprescription drug by the German Commission E for treatment of symptoms of
anxiety, stress, and nervous restlessness (Blumenthal et al., 1998). Kava only recently became a top-selling herbal
dietary supplement in the U.S.,
used by consumers mainly for dealing with feelings of anxiety (Singh and Blumenthal,
1997). The herb ranked ninth in retail sales in mainstream markets (e.g.,
grocery stores, drugstores, and mass market retailers) in the U.S. in 2000,
with annual sales in this channel totaling about $15 million. (Blumenthal,
2001). Additional sales in health food stores, multilevel marketing
organizations, mail order houses, through health professionals, and
miscellaneous channels would probably constitute a total estimated market sales
of over $40 million.
Recently, kava has been implicated in some cases of hepatotoxicity
in Europe (Stoller 2000; Hagemann, 2001) and subsequently in the U.S. (Taylor,
2001; Waller, 2002). The German and Swiss governments have taken regulatory
actions based on this preliminary information (Hagemann, 2001; Stoller, 2000),
with the Swiss banning the sale of the leading acetone-based kava extract and
requiring additional safety data for ethanolic extracts in 2000 (IKS, 2001),
and the Germans withdrawing product licenses in 2002 (BfArM, 2002). The French
government has banned its sale (Anon., 2002b) and the British government and
the dietary supplement industry voluntarily suspended its sale pending
resolution of the question of hepatotoxicity (Woodfield, 2001); in early 2003,
Kava sales were banned in the UK (MCA, 2002).
Previous reviews of kava safety did not include evidence
suggesting the potential for hepatotoxicity. A peer-reviewed assessment of the
safety of kava concluded that “when used in normal therapeutic doses, kava
appears to offer safe and effective anti-anxiety and muscle relaxant actions
without depressing centers of higher thought. The safe use of kava as a dietary
supplement in cultures that do not have historical experiences with its use
depends on responsible manufacturing, marketing, individual consumption
patterns, and education” (Dentali, 1997). One recent meta-analysis of
controlled clinical trials found kava to be safe and effective compared to
placebo in the treatment of anxiety (Pittler and Ernst, 2002; 2000), and a
small clinical study on its adverse effects profile concluded that the herb is
relatively safe, not finding significant concerns of hepatotoxicity (Connor et al., 2001). A toxicological review of
kava-associated hepatic adverse event reports (AERs) from Europe and the U.S.
concluded that based on the available data “there is no clear evidence that the
liver damage reported in the U.S. and Europe was caused by the consumption of
kava” (Waller, 2002) (see more below at Adverse Effects). A detailed review of
the chronology of the events related to kava and its alleged association with hepatotoxicity,
plus updates on recent developments, is available on the American Botanical
Council website (ABC, 2001; Blumenthal, 2002b).
Description
German pharmacopeial-grade kava consists of the mostly
peeled, chopped and dried rhizomes of Piper
methysticum G. Forst. [Fam. Piperaceae],
usually freed from the roots, containing not less than 3.5% kavalactones,
calculated as kavain (DAC, 1998). There is a U.S. Pharmacopeia-National
Formulary (USP-NF) kava monograph in development, requiring the dried
rhizome, usually peeled and cut in pieces with the roots removed, containing
not less than 4.5% of kavalactones (USPC, 2002). Because the peeled skin
contains a greater concentration of kavalactones, many extractors use this
non-official plant source and/or the unpeeled root and rhizome and occasionally
the stems. Commercial kava extracts are commonly standardized to 30–40%
kavalactones for dried powdered extracts, and 55–70% for concentrated extracts
and pastes.
Note:
Monographs
for two kava preparations are also in process to become official in the USP-NF:
(1) Powdered Kava Extract (drug-to-extract ratio 6–20:1, contains not less than
30% kavalactones) and (2) Semisolid Kava Extract (drug-to-extract ratio
13–20:1, contains not less than 50% kavalactones) (USPC, 2000).
Primary Use
Neurology
Anxiety disorder (Pittler and Ernst, 2002, 2000;
Blumenthal et al., 1998; Singh et al., 1998; Volz and Kieser, 1997;
Lehmann et al., 1996; Woelk et al., 1993; Warnecke,1991; Kinzler et al., 1991; Lindenberg and
Pitule-Schödel, 1990)
Other Potential Uses
Sleep disorder (Emser and Bartylla, 1991)
Stress and restlessness (Blumenthal et al., 1998)
Muscle relaxant (Dentali, 1997)
Dosage
Daily dosage for cut dried rhizome and other galenical
preparations for oral use equivalent to 60–120 mg kavalactones (aka
kavapyrones) (Blumenthal et al.,
1998; DAC, 1998). 60–120 mg of kavapyrones (kavalactones) is equivalent to
1.7–3.4 g of dried rhizome based on the DAC quantitative requirement of minimum
3.5% (35 mg/g) kavapyrones (kavalactones) (DAC, 1998).
Crude preparations
Cold macerate: The
fresh or dried rhizome is ground to a powder (traditionally it is masticated to
a pulp) and then macerated in cold water. The first filtrate is strained and drunk.
The residue is then compressed and the second filtrate can either be mixed with
the first or consumed separately (Lebot and Cabalion, 1988). A standard bowl of
the traditionally prepared cold macerate beverage contains about 250 mg of
kavalactones (Bone, 1993/94).
Dried rhizome:
1.5-3 g daily, divided throughout the day, chewed well (Bone, 1993/94; Burgess,
1998).
Fluid extract:
(1:2): 3-6 mL daily, divided throughout the day (Bone 1993/94; Burgess, 1998).
Standardized preparations
Capsules or tablets:
Powdered dry extract (not less than 30% kavalactones) or semisolid (paste)
extract (not less than 50% kavalactones) in daily dosage equivalent to 70–280
mg kavalactones. Most controlled clinical trials are based on three 100 mg
doses of a dried extract (acetone solvent), standardized to 70 mg (70%)
kavalactones, or 210 mg kavalactones per day (Pittler and Ernst, 2002, 2000).
Duration of Administration
The Commission E monographs published in 1990 recommended
that kava not be used for more than three months without medical supervision (Blumenthal et al., 1998). The purpose for this limitation was based not on
concerns of potential toxicity of kava (no adverse side effects were noted in
the monograph, based on observations at that time), but on the Commission E’s
desire to ensure that patients using kava for anxiety-related conditions were
not doing so on a self-medication basis and were receiving adequate
professional supervision every three months, especially since kava was seen as
a drug lacking a clear European tradition. Thus, it was considered prudent to
monitor the patient after three months (Busse, 2002a).
Because some of the recent reports of adverse liver effects
are associated with the use of kava for one month or less (along with conventional
medications or alcohol, in some cases), the American Botanical Council
suggested in December 2001 as a precautionary measure, based on the information
available at that time, that use longer than one month be monitored by a
qualified healthcare professional (ABC, 2001; Blumenthal, 2002a, b).
Chemistry
Kava root/rhizome contains 3.5–15% kavalactones
(kavapyrones); these include kavain; 5,6–dihydrokavain; methysticin;
dihydromethysticin; yangonin; and desmethoxyyangonin or 5,6-dehydrokavain).
Kava also contains chalcones (flavokavins A, B, and C); 3.2% minerals
(potassium, calcium, magnesium, sodium, aluminum, and iron) and 3.5% amino
acids (Pizzorno and Murray, 1999; He et
al., 1997; Haberlein et al.,
1997; Singh and Blumenthal, 1997; Leung and Foster, 1996; Mack, 1994).
Note:
There are numerous cultivars of kava containing varying proportions of these
compounds. Research by Lebot et al.
(1992) into the relative proportions of the various lactones in kava has
revealed data on the origin of kava and its chemistry which has been modified
through native selection of individual plants, where the chemical makeup of the
kava, not its morphology, correlated with its ethnobotanical use. Thus,
pharmacologically driven selection appears to have created chemical variations
of kava far removed from its wild ancestor (Singh and Blumenthal, 1997).
Pharmacological Actions
Human
Anxiolytic (Pittler and Ernst, 2002, 2000;
Boerner, 2001; Malsch and Kieser, 2001; Scherer, 1998; Volz and Kieser, 1997;
Lehmann et al., 1996; Woelk et al., 1993; Johnson et al., 1991; Kinzler et al., 1991; Warnecke, 1991; Lindenberg
and Pitule-Schödel, 1990);
sedative (Emser and Bartylla, 1991);
reduces hot flashes (Warnecke, 1991);
locally mildly anesthetic (Singh and
Blumenthal, 1997);
improves sleep disorder (Holm et al., 1991; Wheatley, 2001);
can produce altered vision (Garner and
Klinger, 1985).
Animal
Analgesic (Bruggemann and Meyer, 1963;
Hänsel, 1968; Jamieson and Duffield, 1990a);
antispasmodic (Meyer, 1979);
anticonvulsant (Klohs et al., 1959; Kretzschmar et
al., 1970);
sedative (Kretzschmar et al., 1970; Gleitz et al.,
1996b);
neuroprotection (Backhauss and Kriegelstein,
1992a,b; Gleitz et al., 1996c).
In vitro
Muscle-relaxant (without depressing CNS)
(Singh, 1983);
antispasmodic (natural kavain, Martin et al., 2000), (synthetic kavain, Seitz et al., 1997a);
antithrombotic (Gleitz et al., 1997);
inhibitor (reversible) of MAO-B in human
platelets (Uebelhack et al., 1998).
Mechanisms of Action
The following mechanisms have been proposed for kava extract
and/or specific kavalactones:
Decreases levels of the excitatory
neurotransmitter, glutamate (Meldrum, 1985; Ferger et al., 1998);
Activation of mesolimbic dopaminergic
neuron, causing relaxation and slight euphoria (Baum et al., 1998)
Binds to GABA receptors in some regions of
the brain (Davies et al., 1992;
Jussofie, 1993; Jussofie et al.,
1994; Boonen and Haberlein, 1998; Boonen et
al., 2000)
Relaxes muscles through direct action on
muscle contractility; not by inhibition of neuromuscular transmission (Singh,
1983)
Increases delta, theta (daydreaming), and
slow alpha brain wave activity, and decreases fast alpha and beta (concentrating)
activity in a dose-dependent manner (Saletu et
al., 1989)
Interacts with voltage-operated Na+
channels (Gleitz et al., 1996a;
Friese and Gleitz, 1998; Magura et al.,
1997; Schirrmacher et al., 1999)
Inhibits [3H]-noradrenaline
(norepinephrine) uptake (pyrone-specific), contributing to psychotropic
properties (Seitz et al., 1997b)
Blockade of monoamine uptake resulting in
elevation of dopamine and serotonin levels (Seitz et al., 1997a; Boonen et al.,
1998; Baum et al., 1998)
Increases the b/a index in
quantitative electroencephalograms, primarily in the b2-region (in dosages up to 600 mg, administered orally to
humans); thereby exhibiting anxiolytic action without sedative or hypnotic
effects (Johnson et al., 1991)
Kavalactones demonstrate a profile of
cellular actions showing similarity with mood stabilizers (animal) (Grunze et al., 2001)
Contraindications
The Commission E contraindicated the use of kava in cases of
endogenous depression (Blumenthal et al.,
1998). Not for use by persons under 18 years of age (AHPA, 2002; CRN, 2002). In
response to reports of hepatotoxicity that may be associated with use of kava
preparations, the FDA, ABC, and various industry trade organizations have
advised consumers of the rare but potential risk of severe liver injury associated
with the use of kava-containing preparations: Persons who have or have had
liver disease or liver problems, persons taking any medication with known or
suspected hepatotoxic effects, and persons who frequently use alcoholic
beverages should consult a healthcare practitioner before using kava-containing
products. Persons who use a kava-containing product and who experience signs of
illness associated with liver disease should discontinue use and consult their
physician. Symptoms of serious liver disease include jaundice (yellowing of the
skin or whites of the eyes) and brown urine. Non-specific symptoms of liver
disease can include nausea, vomiting, light-colored stools, unusual tiredness,
weakness, stomach or abdominal pain, and loss of appetite (ABC, 2001; AHPA,
2002; Blumenthal, 2002a, b; CRN, 2002; FDA, 2002).
Pregnancy and Lactation:
Kava should not be used during pregnancy or while nursing (Blumenthal et al., 1998; McGuffin et al., 1997).
Adverse Effects
Until recently, reports of adverse effects with recommended
doses of kava have been relatively rare. Extended consumption of large doses
(400 mg kavalactones or more per day for longer than three months) may cause a
scaly, yellowing skin condition (scaly ichthyosis), which resolves itself when
use is discontinued (Mathews et al., 1988;
Ruze, 1990; McGuffin et al., 1997;
Blumenthal et al., 1998). Kava preparations have been reported
to be contributing risk factors for the development of melioidosis, a tropical
disease caused by Burkholderia
pseudomallei (BP) and associated with high mortality. In a prospective
study, 252 cases of BP were found in Australia over a 10-year period.
Consumption of kava was a risk factor in 8% of those cases (Currie et al., 2000). There are two case
reports of necrotizing hepatitis after ingestion of an herbal preparation
containing kava extract and celandine (Chelidonium
majus). Glutamic acid pyruvate transaminase (GPT) levels dropped to normal
in both cases when the herbs were discontinued, suggesting a possible causal
connection. Due to the combination of herbs and lack of confirmed toxicological
data on kava and the liver, and direct cause and effect, it is possible that
these results are due to the celandine and/or the combination (Strahl et al., 1998).
By early 2002, there had been approximately 30 cases of
possible hepatoxicity associated with ingestion of kava reported in
international literature, with at least 28 cases reported in total (Switzerland—4; Germany—24), prompting regulatory
actions by authorities (Hagemann, 2001). The hepatic AERs in these cases include
cholestatic hepatitis (inflamed liver with obstruction of bile flow), icterus
(jaundice), increased liver enzymes (a sign of liver dysfunction), liver cell
impairment, severe hepatitis with confluent necrosis, irreversible liver damage
(required transplant in four cases), etc. Additionally, at least 5 cases of
liver dysfunction purportedly associated with kava consumption have been
reported in the U.S.
(Waller, 2002).
Although much of the data on the reported cases of hepatotoxicity
is either incomplete or generally unavailable, relatively detailed information
has been published for 5 of these cases (Kraft et al., 2001; Russmann et al.,
2001; Brauer et al., 2000; Escher et al., 2001; Sass et al., 2001; Strahl et al.,
1998). In all of these 5 well-documented cases, notes one review, “severe liver
damage or liver failure developed within days. This indicates a sudden, strong
insult to the organ and contrasts with an often long kava intake….” (Schulze
and Siegers, 2002). In the most detailed report, a case of recurring
necrotizing hepatitis was reported in a 39-year old woman who may have consumed
an ethanolic-based kava extract (Strahl et
al., 1998). In a 50-year old man a relation between ingestion of kava and
fulminant hepatic failure was suggested by the chronology, histological
findings, and exclusion of other causes of hepatitis. He reportedly took no
other drugs nor did he consume alcohol, yet his liver function tests showed a
60-fold and 70-fold increase in aspartate aminotransferase (AST) and alanine aminotransferase
(ALT) concentrations, respectively (Escher et
al., 2001).
Although kava consumption is considered relatively risk free
in its native regions in Polynesia, heavy kava consumption has been associated
with increased concentrations of glutamyltransferase, suggesting potential
hepatotoxicity (in a population known to be relatively heavy consumers of
alcohol), according to a report of its use in Australian aboriginal people
(Mathews et al., 1988).
In response to the potential for hepatoxicity, the German
Federal Institute for Drugs and Medical Devices (BfArM) called for labeling of
such potential risk on package inserts in kava products (BfArM, 2000). Swiss
authorities have taken similar measures after four cases were reported
(Stoller, 2000). Seen in perspective to total estimated consumption of kava
doses, these cases would constitute one case per 10 million daily doses (Busse,
2000).
Several reviews of these reports emphasize that many of
these cases noted other known or suspected liver-toxic medications (e.g.,
diclofenac and others in Europe; docusate, Ogen®, Percocet®,
Celexa®, Oxycontin®, Coumadin®, Celebrex®,
and others) had been administered concurrently; in most of the other cases the
possibility that concurrently ingested medications, alcohol or virus infections
could not be ruled out as possible causes (Schmidt, 2001, 2002; Schulz and
Siegers, 2002; Waller 2002). Thus, only a few cases can be conclusively linked
to the use of kava (e.g., a case in which liver enzyme values were elevated
upon re-exposure to kava after an initial presentation of necrotizing hepatitis
[Strahl et al., 1998]). One review
suggests that the elucidation of possible mechanisms would add evidence of a
causal relationship but that the current animal safety data are scarce and
indicate a low hepatotoxic potential (Schulze and Siegers, 2002). An analysis
of the approximately 30 hepatic AERs from Europe and 5 submitted to the U.S.
FDA from May 1998 through September 2001 by an American toxicologist concluded
that there is “no clear evidence that the liver damage reported in the U.S. and
Europe was caused by the consumption of kava” and that those cases in which
there is a possible association between the use of a kava extract and liver
dysfunction “appear to have been hypersensitivity or idiosyncratic base
responses.” (Waller, 2002). However, the report’s author acknowledged that he
did not have adequate medical information on all the case reports to adequately
assess them. Two U.S.
case reports suggest relative safety of kava. In one case in which four
prescription drugs plus relatively high levels of kava were used (300 pills or
45,000 mg per day) there was no liver damage observed; in another case a
13-year old girl consumed 8–10, 500 mg tablets in a suicide attempt, but
recovered the following morning. “From a toxicologist perspective, these two
cases provide some evidence that kava itself is not a direct hepatotoxin even
in extremely high concentrations.” (Waller, 2002).
The report concludes:
…kava when taken in
appropriate doses for reasonable periods of time has no scientifically
established potential for causing liver damage. However as with any
pharmacologically active agent, there is always the possibility of drug
interactions, preexisting disease conditions and idiosyncratic or
hypersensitivity reactions, which can exacerbate the toxicity of such an agent.
Increased surveillance or reports of adverse effects and judicious use of
kava-derived products under the conditions recommended by the natural products
industry would be a most prudent approach to confirm its safety and minimize
any risk of liver damage. The medical community and the general public should
be made aware that concomitant intake of prescription drugs associated with
liver damage, excessive alcohol consumption and preexisting liver disease or
hepatitis with compromised liver function are conditions which may preclude any
kava consumption (Waller, 2002).
A recent pilot study on an American kava extract (KavaPure®,
PureWorld, South Hackensack,
NJ) assessed the potential
adverse effects profile of kava (Connor et
al., 2001). The study concluded that there were no significant differences
between kava and placebo on any of the parameters evaluated, including
withdrawal symptoms, heart rate, blood pressure, laboratory assessments, and
sexual function; there were slightly elevated liver enzymes in 3 kava patients
(one at baseline) which was not deemed clinically significant by the authors.
Drug Interactions
Simultaneous consumption of kava with alcohol, barbiturates,
psychopharmacological drugs, or other substances acting on the central nervous
system (CNS) may potentiate inebriation or the CNS depressant effect, according
to Commission E, based on a variety of evidence, including speculation
(Blumenthal et al., 1998). Regarding
interactions with alcohol, subjective measures of sedation, cognition,
coordination and intoxication were increased in a clinical trial (n=20) in
doses of 1gm/kg kava with alcohol (Foo & Lemon, 1997). Despite kava’s
producing an increase in the hypnotic effect of ethanol in rats (Jamieson and
Duffield, 1990b), an 8-day human trial (n=20) using Laitan® (W.
Schwabe, Germany) at 300 mg per day did not produce negative additive effects;
the kava group even showed increased scores on the concentration test on the
4th day (Herberg, 1993).
Kava may potentiate effects of other anxiolytics, and may
increase Parkinson symptoms by reducing the effect of levodopa, possibly due to
dopamine antagonism, according to one human case report (Ernst, 2000; Brinker,
2001). There is one case report of “coma” associated with the combined use of
kava and the benzodiazepine, alprazolam (Xanax®), cimetidine
(Tagamet®), and terazosin (Hytrin®) (Almeida and
Grimsley, 1996). There are reports of interactions, some profound, between
alprazolam and cimetidine since 1983 (Abernathy et al., 1983). Cimetidine can reduce the hepatic clearance of
alprazolam; thus, the simultaneous use of the two drugs increases levels of
alprazolam. Terazosin, a hypotensive drug used for benign prostatic
hyperplasia, is usually not noted for interactions with other drugs; however, a
commonly reported side effect is “dizziness” and “somnolence” (Abbott Labs,
2002), which might help explain the disorientation of the patient. Since this
disorientation (despite the title of the report there was no loss of
consciousness (in the article the authors refer to a “semicomatose state”),
began 3 days after the first use of kava, it is possible that kava may have
triggered the adverse event, but the extent that a possible chronic overdose of
alprazolam, plus the possible side effect of terazosin, or a combination of
both, may have contributed to the “lethargic” state of the patient is not clear
(Bergner, 1999).
American Herbal Products Association (AHPA) Safety Rating
Class 2b: Not
to be used during pregnancy.
Class 2c: Not
to be used while nursing.
Class 2d:
Caution is required when driving or operating other equipment, and simultaneous
consumption of kava and alcohol or barbiturates may potentiate inebriation
(McGuffin et al., 1997).
Regulatory Status
Australia:
Schedule 4 to the Customs (Prohibited Imports) Regulations and is listed on
Appendix B-“Substances Subject to Import Controls” with annual license and
permit required. Importation of kava into the Northern
Territory not permitted, and clearance from the State Health
authorities required for importation into Western Australia (TGA, 2000a, 2000b). The
Australian Therapeutic Goods Administration (TGA) reviewed kava’s legal status
and invited submissions for consideration (Burgess, 1998). In 2002, the TGA
ordered a voluntary recall on the sale of kava based on the prevailing
international concerns over potential association with hepatotoxicity (Worth,
2002).
Canada: Kava
is not acceptable as a nonmedicinal ingredient in oral-use products (HPB, 1993;
Health Canada 1995a). When identified as a Traditional Herbal Medicine (THM) or
a homeopathic drug, kava was formerly regulated as a schedule OTC drug
requiring premarket authorization and assignment of a Drug Identification
Number (DIN) (Health Canada, 1995b, 2001; WHO, 1998). Health Canada reviewed
the safety of kava in light of the recent hepatotoxicity reports (Anon, 2002a)
and banned the sale of kava, and issued a product recall in August 2002 (Health
Canada, 2002).
France: No
monograph in the French Pharmacopoeia.
Kava products banned by Ministry of Health in January 2002 due to concerns over
potential hepatotoxicity (Anon., 2002b).
Germany: Product
licenses withdrawn (BfArM, 2002).
Sweden: Approved for use as a drug (De Smet et al., 1993).
Switzerland: Dry
native extract 10–23:1 (w/w)
available in solid dosage form (capsule or tablet) is classified by the Interkantonale Kontrollstelle für Heilmittel (IKS) as a List D medicinal product,
requiring premarketing authorization and product license, with sales limited to
pharmacies and drugstores, without prescription (AKS, 2001; Ruppanner and
Schaefer, 2001; WHO, 1998). In 2000 the IKS withdrew the license for the
acetonic kava product standardized to 70% kavalactones, owing to concerns of
possible hepatotoxicity, based on AERs (see Adverse Effects above), despite the
fact that most of the serious kava AERs implicated ethanolic extracts. The
acetone extract dominates about 80% of the Swiss market, and was thus the first
extract to produce AERs. Manufacturers of ethanolic extracts are allowed to
maintain their products on the market for three years, during which time they
must produce toxicology, pharmacology, and clinical studies on their respective
extracts (Busse, 2002b).
U.K.: Kava
was formerly an herbal medicine on the General
Sale List, Schedule I (requiring full Product License), Table A (internal
or external use) with maximum single-dose of 625 mg (GSL, 1994). In December
2001 the British Medicines Control Agency (MCA) and the dietary supplement
trade organizations agreed to voluntarily suspend the sales of kava until such
time as the issue of potential hepatotoxicity was adequately resolved
(Woodfield, 2001). In December 2002, MCA announced a ban on Kava effective
January 2003 (MCA, 2002).
U.S.: Dietary
supplement (USC, 1994). Kava Rhizome, Powdered Kava, Powdered Kava Extract,
Semisolid Kava Extract and Kava Tablets are subjects of botanical monographs in
development for United States
Pharmacopeia-National Formulary. Previews of the standards development were
published in the Pharmacopeial Forum
(USPC, 2000; 2002). In March 2001, the FDA issued a public warning on kava in
response to concerns about potential hepatotoxicity (FDA, 2002).
Clinical Review
Fifteen studies are outlined in the following table, “Clinical
Studies on Kava”, including 669 participants. These studies demonstrated kava’s
positive effects for indications including anxiety, mental function, reaction
time, sleep quality, and peri-menopausal symptoms, while one study (Connor et al., 2001) focused on the safety of
kava. Six randomized, double-blind, placebo-controlled (R, DB, PC) studies have
been performed on 357 participants, concluding that kava significantly reduced
anxiety in several different populations (Malsch and Kieser, 2001; Singh et al., 1998; Volz and Kieser, 1997;
Lehmann et al., 1996; Warnecke et al., 1991; Kinzler et al., 1991). One R, DB, case-controlled
study of 172 participants found a significant reduction in anxiety (Woelk et al., 1993). Two DB, crossover (CO)
trials showed that mental clarity remains intact with kava use (Heinze et al., 1994; Munte et al., 1993). Kava demonstrated a favorable influence on sleep in
one PC, CO study (Emser and Bartylla, 1991). One PC, CO, comparison trial
showed that kava did not affect reaction time or impair safety, compared to
bromazepam and bromazepam combined with kava (Herberg, 1996). A highly
significant improvement in peri-menopausal symptoms was demonstrated in a R,
DB, PC study (Warnecke et al., 1990).
A meta-analysis of seven R, DB, PC trials conducted on various doses of kava,
confirmed an anxiolytic effect and demonstrated it was significantly superior
to placebo as a symptomatic treatment for anxiety (Pittler and Ernst, 2002,
2000). The Cochrane Review has designed a protocol for evaluating R, DB, PC
trials of Kava for anxiety, but has not concluded their evaluation (Bent et al., 2001). In one PC pilot study
(n=13), the preliminary findings suggest that kava might exert a positive
effect on reflex vagal control of heart rate in generalized anxiety disorder
patients (Watkins et al., 2001).
Another R, DB, PC study by some of these same authors reviewed the safety
profile of kava in 35 subjects. No
significant differences were found between kava and placebo on any of the
parameters evaluated, including withdrawal symptoms, heart rate, blood
pressure, laboratory assessments, and sexual function, with slightly elevated
liver enzymes in 3 kava patients (one was elevated at baseline) which was not
deemed clinically significant (Connor et
al., 2001).
Branded Products*
GITLY kava extract: Produced as 400 mg tablets containing 120
mg kavalactone. Product manufacturer and distributor not identified.
KavaPure®: PureWorld Botanicals Inc. / 375 Huyler St. / South Hackensack, NJ 07606 / U.S.A. / Tel: (201) 440-5000 / Fax:
(201) 342-8000 / www.pureworld.com. Powdered
extract of kava rhizome standardized to 30% kavalactones.
Kavatrol®: Natrol Inc. / 21411 Prairie Street / Chatsworth,
CA 91311
/ U.S.A.
/ Tel: (800) 326-1520 / www.natrol.com. Produced from dried kava roots in a
multistage process. Packaged in 200 mg capsules, containing 60 mg kavalactones
in each capsule.
Kavosporal®: Polcopharma F Polley & Co. / P.O. Box 100 /
Epping / NSW 1710 / Australia
/ Tel: +61-02-98-7664 / Fax: +61-02-98-6822-6 / Email: sales@polcopharma.com /
http://polcopharma.com.au.
Laitan®: Dr. Willmar Schwabe Pharmaceuticals /
International Division / Willmar Schwabe Str. 4 / D-76227, Karlsruhe
/ Germany
/ Tel: +49-721-4005 ext. 294 / Email: melville-eaves@schwabe.de /
www.schwabepharma.com. Standardized to
70% kavalactones.
Laitan® 100: Dr. Willmar Schwabe Pharmaceuticals.
Packaged in 100 mg capsules, each standardized to contain 70 mg kavalactones.
WS 1490: Dr. Willmar Schwabe Pharmaceuticals. Standardized
to 70% kavalactones.
*American equivalents, if any, are found in the Product
Table beginning on page 398.
References
Abbott Laboratories. Hytrin website 2002 Feb. Available from: URL:
http://www.rxabbott.com/pdf/hytrin.
ABC. See: American Botanical Council.
Abernethy DR, Greenblatt DJ, Divoll M, Moshitto LJ, Harmatz JS, Shader RI.
Interaction of cimetidine with the triazolobenzodiazepines alprazolam and
triazolam. Psychopharmacology 1983;80(3):275–8.
AHPA. See: American Herbal Products Association.
AKS. See: Arzneimittel-Kompendium der
Schweiz.
Almeida JC, Grimsley EW. Coma from the health food store: interaction
between kava and alprazolam. Ann Intern
Med 1996;125(11):940–1.
American Botanical Council (ABC). American Botanical Council announces new
safety information on kava [press release]. Austin (TX): 2001 Dec. 20.
American Herbal Products Association (AHPA). Kava product warning label
issued by leading herbal association [press release]. Silver Spring (MD): 2002
Mar 27 [cited 2002 Nov 7]. Available from: URL:
http://www.ahpa.org/pr_032702.htm.
Anon. Health Canada issues kava alert. Toronto
Star 2002a Jan 17.
Anon. Pacific island beverage banned in France after hepatitis scare. Agence France-Presse 2002b Jan 9.
Arzneimittel-Kompendium der Schweiz™
(AKS). Produktinformation und Patienteninformation: Kavasol®; Kavasedon®.
Basel, Switzerland: Documed AG; 2001.
Backhauss C, Krieglstein J. Extract of kava (Piper methysticum) and its methysticin constituents protect brain
tissue against ischemic damage in rodents.
Eur J Pharmacol 1992a;215(2–3):265–9.
Backhauss C, Krieglstein J. Neuroprotective activity of kava extract (Piper methysticum) and its methysticin
constituents in vivo and in vitro. In: Krieglstein J, Oberpichler-Schwenk H,
editors. Pharmacology of Cerebral
Ischemia. Stuttgart, Germany: Wissenschftliche Verlagsgellschaft GmBH;
1992b. p. 501–507.
Baum SS, Hill R, Rommelspacher H. Effect of kava extract and individual
kavapyrones on neurotransmitter levels in the nucleus accumbens of rats. Progress Neuro-Psychopharmacology Biol Psych
1998;22(7):1105–20.
Bent S, Tsourinas C, Romoli M, Linde K. Kava for Anxiety Disorder. In: The Cochrane Library. 2001;1.
Bergner P. Piper—A second opinion on herb-drug interaction. Medical Herbalism 1999;11(1):16,20.
BfArM. See: Bundesinstitut für Arzneimittel und Medizinprodukte [The German
Federal Institute for Drugs and Medical Devices].
Blumenthal M. The Safety of Kava Questioned: Link to possible liver
toxicity subject of inquiries. Texas Pharmacy
2002a Spring;14–7,20–1,34.
Blumenthal M. Kava safety questioned due to case reports of liver toxicity:
expert analyses of case reports say insufficient evidence to make causal
connection. HerbalGram.
2002b;55:26–32. Also available from: URL: http://www.herbalgram.org/browse.php?content_name=kavaupdate
Blumenthal M. Herb sales down 15% in mainstream market. HerbalGram 2001;51:69.
Blumenthal M, Goldberg A, Brinckmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Austin (TX):
American Botanical Council; Newton (MA): Integrative Medicine Communications;
2000.
Blumenthal M, Busse WR, Goldberg A, Gruenwald J, Hall T, Riggins CW, Rister
RS, editors. Klein S, Rister RS (trans.). The
Complete German Commission E Monographs—Therapeutic Guide to Herbal Medicines.
Austin (TX): American Botanical Council; Boston (MA): Integrative Medicine
Communication; 1998. p. 156–7.
Boerner RJ. Kava kava in the treatment of generalized anxiety disorder,
simple phobia and specific social phobia. Phytotherapy
Research 2001;15(7):646–7.
Bone K. Kava—A safe herbal treatment for anxiety. Brit J Phytotherapy 1993/94;3(4):147–153.
Boonen G, Häberlein H. Influence of genuine kavapyrone enantiomers on the
GABA-A binding site. Planta Medica 1998;64(6):504–506.
Boonen G, Ferger B, Kuschinsky K, Häberlein H. In vivo effects of the
kavapyrones (+)–dihydromethysticin and (+/-)–kavain
on dopamine, 3,4–dihydroxyphenylacetic acid, serotonin, and
5–hydroxyindoleacetic acid levels in striatal and cortical brain regions. Planta Medica 1998;64(6):507–510.
Boonen G, Pramanik A, Rigler R, Häberlein H. Evidence for specific
interactions between kavain and human cortical neurons monitored by
fluorescence correlation spectroscopy.
Planta Medica 2000;66(1):7–10.
Brauer RB, Pfab R, Becker K, et al.
Fulminantes Leberversagen nach Einnahme des pflanzlichen Heilmittels Kava-Kava.
Z Gastroenterologie 2000;39:491.
Brinker F. Herb Contraindications and
Drug Interactions. 3d ed. Sandy (OR): Eclectic Medical Publications; 2001.
p. 125–127.
Bruggemann F, Meyer H. Studies on the analgesic efficacy of the kava
constituents dihydrokavain (DHK) and dihydromethysticin (DHM) [in German]. Arzneimittelforschung 1963;13:407–9.
Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) [The German
Federal Institute for Drugs and Medical Devices]. BfArM recalls permisisons for
kava and kavain products [press release; in German]. 2002 Jun 17 [cited 2002
Jul 15]. Available from: URL: http://www.bfarm.de/de_ver/presse/02_10de.html.
Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) [The German
Federal Institute for Drugs and Medical Devices]. Introduction of a drug safety
plan for pharmaceutical products containing kava-kava. (July 24, 2000).
Burgess N. Regulatory issues on Piper
methysticum (kava). Aust J Med Herb
1998;10(1):2–3.
Busse WR. (W. Schwabe Co.). Personal communication to M. Blumenthal. Feb.
25, 2002a.
Busse WR. (W. Schwabe Co.). Personal communication to M. Blumenthal. Jan.
23, 2002b.
Busse WR. (W. Schwabe Co.). Schwabe position on kava extracts and liver
toxicity [unpublished]. 2000.
Connor KM, Davidson JRT, Churchill LE. Adverse-effect profile of kava. CNS Spectrums 2001;6(10):848–853.
Council for Responsible Nutrition. CRN complements FDA consumer advisory on
kava with recommendation for voluntary cautionary labels [press release].
Washington (DC): 2002 Mar 28 [cited 2002 Nov 7]. Available from: URL:
http://www.crnusa.org/shellnr032702.html.
CRN. See: Council for Responsible Nutrition.
Currie BJ, Fisher DA, Howard DM, Burrow JN, Lo D, Selva-Nayagam S, et al. Endemic melioidosis in tropical
northern Australia: a 10-year prospective study and review of the literature
[review]. Clin Infect Dis
2000;31(4):981–6.
DAC. See: Deutscher
Arzneimittel-Codex.
Davies LP, Drew CA, Duffield P, Johnston GA, Jamieson DD. Kava pyrones and
resin: studies on GABA-A, GABA-B, and benzodiazepine binding sites in rodent
brain. Pharm Toxicol
1992;71(2):120–6.
De Smet PAGM, Keller K, Hansel R, Chandler RF, editors. Adverse Effects of Herbal Drugs 2.
Berlin, Germany: Springer-Verlag; 1993.
Dentali SJ. Herb Safety Review: kava – Piper
methysticum Forster f. (Piperaceae).
Silver Spring (MD): Kava Committee of the American Herbal Products Assn.; 1997.
Deutscher Arzneimittel-Codex
(DAC). Ergänzungsbuch zum Arzneibuch, Band II. Stuttgart, Germany: Deutscher
Apotheker Verlag; 1998;K-155:1–6.
Duffield AM, Jamieson DD, Lidgard RO, Duffield PH, Bourne DJ.
Identification of some human urinary metabolites of the intoxicating beverage
kava. J Chromatogr 1989;475:273–81.
Emser W, Bartylla K. Improvement in quality of sleep: effect of kava
extract WS 1490 on the sleep patterns in healthy people. TW Neurologie Psychiatrie 1991;5:636–42.
Ernst E. Possible interactions between synthetic and herbal medicinal
products. Perfusion 2000;13:4–15.
Escher M, Desmeules J, Giostra E, Mentha G. Hepatitis associated with kava,
a herbal remedy for anxiety [published erratum appears in BMJ 2001;322(7294):1097]. BMJ
2001;322(7279):139.
FDA. See United States Food and Drug Administration.
Ferger B, Boonen G, Häberlein H, Kuschinsky K. In vivo microdialysis study
of
(+/-)-kavain on veratridine–induced
glutamate release. Eur J Pharmacol 1998;347(2–3):211–4.
Foo H, Lemon J. Acute effects of kava, alone or in combination with
alcohol, on subjective measures of impairment and intoxication and on cognitive
performance. Drug Alcohol Rev
1997;16:147-155. In: Brinker F. Herb
Contraindications and Drug Interactions. 3d ed. Sandy (OR): Eclectic
Medical Publications; 2001. p. 125–127.
Forster G. A Voyage round the World
in his Britannic Majesty’s Sloop, Resolution, commanded by Capt. James Cook during the years 1772, 3, 4, and 5. vol
2. London, U.K.: B. White;1777. p. 406–8.
Friese J, Gleitz J. Kavain, dihydrokavain and dihydromethysticin
non-competitively inhibit the specific binding of [3H]-batrachotoxinin-A
20-alpha-benzoate to receptor site 2 of voltage-gated Na+ channels. Planta Med 1998;64(5):458–9.
Garner LF, Klinger JD. Some visual effects caused by the beverage kava.
J Ethnopharmacol 1985;13(3):307–11.
General Sale List (GSL).
Statutory Instrument 1994 No. 2410; The Medicines (Products Other Than
Veterinary Drugs) (General Sale List)
Amendment Order 1994. London, U.K.: Her Majesty’s Stationery Office (HMSO);
1994.
Gleitz J, Beile A, Wilkens P, Ameri A, Peters T. Antithrombotic action of
the kava pyrone (+)-kavain prepared from Piper
methysticum on human platelets. Planta
Medica 1997;63(1):27–30.
Gleitz J, Friese J, Beile A, Ameri A, Peters T. Anticonvulsive action of
(+/-)-kavain estimated from its properties on stimulated synaptosomes and Na+
channel receptor sites. Eur J Pharmacol
1996a;315(1):89–97.
Gleitz J, Gottner N, Ameri A, Peters T. Kavain inhibits
non–stereospecifically veratridine–activated Na+–channels. Planta Medica 1996b;62:580–581.
Gleitz J, Tosch C, Beile A, Peters T. The protective action of tetrodotoxin
and
(+/-)–kavain on anaerobic glycolysis, ATP content, and intracellular Na+ and
Ca2+ of anoxic brain vesicles. Neuropharmacol
1996c;35(12):1743–52.
Gleitz J, Beile A, Peters T. (+/-)-Kavain inhibits veratridine-activated
voltage-dependent Na+ channels in synaptosomes prepared from rat cerebral
cortex. Neuropharmacol
1995;34(9):1133–8.
GSL. See: General Sale List.
Grunze H, Langosch J, Schirrmacher K, Bingmann D, Von Wegerer J, Walden J.
Kava pyrones exert effects on neuronal transmission and transmembraneous cation
currents similar to established mood stabilizers—a review. Prog Neuropsychopharmacol Biol Psychiatry 2001;25(8):1555–70.
Haberlein H, Boonen G, Beck MA. Piper
methysticum: enantiomeric separation of kavapyrones by high performance
liquid chromatography. Planta Med
1997;63:63–5.
Hagemann U. Pharmaceutical products containing kava kava (Piper methysticum) and kavain, including
homeopathic preparations with a final concentration up to D6 [letter]. Berlin:
German Federal Institute for Drugs and Medical Devices (BfArM). Nov. 8, 2001.
Hänsel R. Characterization and physiological activity of some kava
constituents. Pac Sci
1968;22:293–313.
He X, Lin L, Lian L. Electrospray high performance liquid
chromatography-mass spectrometry in phytochemical analysis of kava extract. Planta Med 1997;63:70–4.
Health Canada. Health Canada issues a stop-sale order for all products
containing kava. 2002 Aug 21 [cited 2002 Nov 11]. Available from: URL: http://www.hc-sc.gc.ca/english/protection/warnings/2002/2002_56e.htm.
Health Canada. Drug Product Database (DPD) Product Information. Ottawa, Ontario:
Health Canada Therapeutic Products Programme; 2001.
Health Canada. Drugs Directorate
Guidelines: Traditional Herbal Medicines. Ottawa, Ontario: Minister of
National Health and Welfare, Canada; 1995b. p. 1–11.
Health Canada. Herbs used as non-medicinal ingredients in nonprescription
drugs for human use—Appendix II: list of herbs unacceptable as non-medicinal
ingredients in oral use products subject to part B. Ottawa, Ontario: Health
Canada Drugs Directorate Bureau of Nonprescription Drugs; 1995a. p. 1–22.
Health Protection Branch. HPB Status
Manual. Ottawa, Ontario: Health Protection Branch; 1993 Feb 19. p. 111.
Heinze HJ, Münthe TF, Steitz J, Matzke M. Pharmacopsychological effects of
oxazepam and kava kava extract in a visual search paradigm assessed with
event-related potentials. Pharmacopsychiatry
1994;27(6):224–230.
Herberg KW. Safety-related performance after intake of kava-extract,
bromazepam and their combination [in German]. Z Allg Med 1996;72:973–77.
Herberg KW. Effect of Kava-Special Extract WS 1490 combined with ethyl
alcohol on safety-relevant performance parameters [in German]. Blutalkohol 1993;30(2):96–105. In:
Brinker F. Herb Contraindications and
Drug Interactions. 3d ed. Sandy (OR): Eclectic Medical Publications; 2001.
p. 125–7.
Holm E, Staedt U, Hepp J, Kortsik C, Behne F, Kaske A, et al. The action profile of D,L-kavain: cerebral sites and
sleep-wakefulness-rhythm in animals [in German]. Arzneimittelforschung 1991:41(7):673–83.
HPB. See: Health Protection Branch.
IKS. See: Interkantonalen Kontrollstelle für Heilmittel.
Interkantonalen Kontrollstelle für Heilmittel (IKS). Monatsbericht der IKS. Bern, Switzerland: IKS; 2001 April. p. 220.
Jamieson DD, Duffield PH. The antinociceptive actions of kava components in
mice. Clin Exp Pharm Physiol
1990a;17(7):495–507.
Jamieson DD, Duffield PH. Positive interaction of ethanol and kava resin in
mice. Clin Exp Pharm Physiol
1990b;17(7):509–14.
Johnson D, Frauenddorf A, Stecker K, Stein U. Neurophysiological activity
profile and tolerability of Kava-Extract WS 1490 [in German]. Neurol/Psychiat 1991;5:584–88.
Jussofie A, Schmiz A, Hiemke C. Kavapyrone enriched extract from Piper methysticum as modulator of the
GABA binding site in different regions of rat brain. Psychopharmacol 1994;116(4):469–74.
Jussofie A. Brain area specific differences in the effects of neuroactive
steroids on the GABA-A receptor complexes following acute treatment with
anaesthetically active steroids. Acta
Endocrinology 1993;129(5):480–5.
Kilham C. Kava: Medicine Hunting in
Paradise. Rochester (NY): Inner Traditions; 1996.
Kinzler E, Kromer J, Lehmann E. Effect of a special kava extract in
patients with anxiety-, tension-, and excitation states of non-psychotic
genesis: double blind study with placebos over 4 weeks [in German]. Arzneimittelforshung 1991;41(6):584–8.
Klohs M, et al. A chemical and
pharmacological investigation of Piper methysticum
Forst. J Med Pharm Chem 1959;1:95–9.
Kraft M, Spahn TW, Menzel J, Senninger N, Dietl KH, Herbst H, et al. Fulminant liver failure after
administration of the herbal anti-depressant kava-kava [in German]. Dtsch Med Wochenschr 2001;126(36):970–2.
Kretszchmar R. Kavain psychopharmakon. München
Med Wochenschr 4ème année 1970;112:154–8.
Lebot V, Cabalion P. Technical Paper No. 195: Kavas of Vanuatu–Cultivars of
Piper methysticum Forst. Noumea, New
Caledonia: South Pacific Commission; 1988. p. 13–15.
Lebot V, Merlin M, Lindstrom L. Kava:
The Pacific Drug. New Haven (CT): Yale University Press; 1992.
Lehmann E, Kinzler E, Friedemann J. Efficacy of a special Kava extract (Piper methysticum) in patients with
states of anxiety, tension and excitedness of non-mental origin—a double-blind
placebo-controlled study of four weeks treatment. Phytomedicine 1996;3(2):113–9.
Leung A, Foster S. Encyclopedia of
Common Natural Ingredients Used in Food, Drugs, and Cosmetics. 2nd ed. New
York (NY): John Wiley and Sons; 1996.
Liberti L, editor. Kava Monograph. Lawrence
Review of Natural Products. Levittown (PA): Pharmaceutical Information
Associates; 1987.
Lindenberg D, Pitule-Schödel H. D,L-kavain in comparison with oxazepam in
anxiety disorders. a double-blind study of clinical effectiveness [in German]. Forschr Med 1990;108(2):50–4.
Mack R. Kava kava. Piper methysticum–a
unique economic plant of the Pacific Islands.
J Health Sci 1994;1(1):43–8.
Magura EI, Kopanitsa MV, Gleitz J, Peters T, Krishtal OA. Kava extract
ingredients, (+)-methysticin and (+/-)-kavain inhibit voltage-operated
Na+-channels in rat CA 1 hippocampal neurons. Neuroscience 1997;81(2):345–51.
Malsch U, Kieser M. Efficacy of kava-kava in the treatment of non-psychotic
anxiety, following pretreatment with benzodiazepines. Psychopharmacol 2001;157(3):277–83.
Martin HB, Stofer WB, Eichinger MR. Kavain inhibits murine airway smooth
muscle contraction. Planta Medica 2000;66(7):601–6.
Mathews JD, Riley MD, Fejo L, Munoz E, Milns NR, Gardner ID, et al. Effects of the heavy usage of
kava on physical health: summary of a pilot survey in an Aboriginal community. Med J Aust 1988;148(11):548–55.
MCA. See: Medicines Control Agency (UK).
McGuffin M, Hobbs C, Upton R, Goldberg A, editors. American Herbal Products Association’s Botanical Safety Handbook.
Boca Raton (FL):CRC Press; 1997.
Medicines Control Agency (UK). MCA investigation of kava kava leads to ban
following voluntary withdrawal [press release]. 20 Dec 2002.
Meldrum B. Possible therapeutic applications of antagonists of excitatory
amino acid neurotransmitters [review]. Clin
Sci (Lond) 1985;68(2):113-22.
Meyer HJ. Pharmacology of Kava. In: Efron DH, Holmstedt B, Kline NS,
editors. Ethnopharmacologic Search for
Psychoactive Drugs. New York (NY): Raven Press; 1979. p. 133–40.
Munte TF, Heinze HJ, Matzke M, Steitz J. Effects of oxazepam and an extract
of kava roots (Piper methysticum) on
event-related potentials in a word-recognition task. Pharmacoelectroencephalog 1993;27(1):46–53.
Norton S, Ruze P. Kava dermopathy. J
Am Acad Derm 1994;31(1):89–97.
Pittler MH, Ernst E. Efficacy of kava extract for treating anxiety:
systematic review and meta-analysis. J
Clin Psychopharmacol 2000;20(1):84–9.
Pittler MH, Ernst E. Kava extract for treating anxiety [Cochrane Review].
In: The Cochrane Library; 2002;(2):CD00383.
Pizzorno JE, Murray MT , editors. Textbook
of Natural Medicine, Vol. 1. 2nd ed.
New York (NY): Churchill Livingstone; 1999.
Ruppanner H, Schaefer U (eds.). Kavasedon® Kapseln; Kavasporal® Kapseln;
Laitan® Kapseln; Yakona N® Kapseln. In: Codex
2000/01 — Die Schweizer Arzneimittel in einem Griff. Basel, Switzerland:
Documed AG; 2001. pp. 1208–9, 1244.
Russell P, Bakker D, Singh N. The effects of kava on alerting and speed of
access of information from long-term memory. Bulletin of the Psychonomic Society 1987;25:236–7.
Russmann S, Lauterburg BH, Helbing A. Kava hepatotoxicity. Ann Internal Med 2001;135(1):68–9.
Ruze P. Kava-induced dermopathy: a niacin deficiency? Lancet 1990;335(8703):1442–5.
Saletu B, Grunberger J, Linzmayer L, Anderer P. EEG brain-mapping,
psychometric and psychophysiological studies on the central effects of kavain—a
kava plant derivative. Human
Psychopharmacol 1989;4:169–90.
Sass M, Schnabel S, Kröger J, et al.
Akutes Leberversgaen durch Kava-Kava—eine seltene Indikation zur
Lebertransplantation. Z Gastroenterol
2001;39:491.
Scherer J. Kava-kava extract in anxiety disorders: an outpatient
observational study. Adv Ther 1998;15(4):261–9.
Schirrmacher K, Büsselberg D, Langosch JM, Walden J, Winter U, Bingmann D.
Effects of (+/-)–kavain on
voltage-activated inward currents of dorsal rhizome ganglion cells from
neonatal rats. European
Neuropsychopharmacology 1999;9(1–2):171–6.
Schmidt J. Analysis of kava side effects reports concerning the liver
[unpublished]. Lindenmaier M. Brinckmann J (trans). Courtesy American Herbal
Products Assn.; 2001, Dec 31.
Schmidt M, Nahrstedt A. Is Kava hepatotoxic? Deutsche Apotheker Zeitung 2002;142(9):58–63.
Schulze J, Siegers CP. Toxicity of
kava pyrones—a reappraisal. Brit J
Pharmacology 2002 (submitted).
Schulze J, Meng G, Siegers CP. Safety assessment of kavalactone-containing
herbal drugs in comparison to other psychotropics [abstract from conference of
Swiss Soc. Pharm. and Tox., German Soc. Experimental and Clin. Pharmacol and
Tox., Austrian Pharmacol. Soc.—Oct. 1–2, 2001]. Arch Pharmacol 2001;364(3):R22.
Seitz U, Ameri A, Pelzer H, Gleitz J, Peters T. Relaxation of evoked
contractile activity of isolated guinea-pig ileum by (+/-)–kavain. Planta Medica 1997a;63(4):303-306.
Seitz U, Schüle A, Gleitz J. [3H]-Monoamine uptake inhibition properties of
kava pyrones. Planta Med
1997b;63(6):548–9.
Singh NN, Ellis CR, Singh YN. A double-blind, placebo-controlled study on
the effects of kava (Kavatrol®) on daily stress and anxiety in adults. Alt Ther 1998;4(2):97–8.
Singh YN. Effects of kava on neuromuscular transmission and muscle
contractility.
J Ethnopharmacol 1983;7(3):267–76.
Singh YN. Kava, an overview [review]. J
Ethnopharmacol 1992;37(1):13–45.
Singh YN, Blumenthal M. Kava: An overview. HerbalGram 1997;39:33–57.
Steiner GG. The correlation between cancer incidence and kava consumption. Hawaii Med J 2000;59(11):420–2.
Stoller R. Liver damage and kava extracts. Schweizerische Ärztezeitung 2000;81(24):1335–6.
Strahl S, Ehret V, Dahm HH, Maier KP. Necrotizing hepatitis after taking
herbal remedies [in German]. Dtsch Med
Wochenschr 1998;123(47):1410–4.
Taylor CL. Letter to MDs re: possible kava hepatoxicity [letter]. Food and
Drug Administration, Dec 19, 2001. Available from: URL:
http://www.fda.gov/medwatch/SAFETY/2001/kava.htm.
TGA. See: Therapeutic Goods Administration.
Therapeutic Goods Administration (TGA). Appendix B – Substances Subject to
Import Controls (annual license & permit required). Woden, Australia:
Therapeutic Goods Administration; 2000a May 29. p. 1–7 .
Therapeutic Goods Administration (TGA). Commonly Asked Questions: Importing
Kava and Khat: What are the requirements for the importation of kava? Woden,
Australia: Therapeutic Goods Administration; 2000 May 29. p. 1–11.
Uebelhack R, Franke L, Schewe HJ. Inhibition of platelet MAO–B by kava
pyrone-enriched extract from Piper
methysticum Forster (kava–kava). Pharmacopsychiatry
1998;31(5):187–92.
United States Congress (USC). Dietary Supplement Health and Education Act
of 1994, Pub. L. No. 103–417, 103rd Cong. (1994).
United States Food and Drug Administration, Center for Food Safety and
Applied Nutrition. Kava-containing dietary supplements may be associated with
severe liver injury [consumer advisory]. 2002 Mar 25 [cited 2002 Nov 7].
Available from: http://www.cfsan.fda.gov/%7Edms/addskava.html.
United States Pharmacopeial Convention (USPC). Pharmacopeial previews.
monographs (NF): kava; powdered kava.Pharmacopeial
Forum 2002 Jan–Feb;28(1).
United States Pharmacopeial Convention (USPC). Pharmacopeial previews.
monographs (NF): powdered kava extract; semisolid kava extract. Pharmacopeial Forum 2000
May–Jun;26(3):42–50.
USC. See: United States Congress.
USPC. See: United States Pharmacopeial Convention.
Volz H-P, Kieser M. Kava kava extract WS 1490 versus placebo in anxiety
disorders — a randomized placebo controlled 25 week outpatient trial. Pharmacopsychiatr 1997;30(1):1–5.
Waller DP. Report on Kava and Liver Damage. Silver Spring (MD): American Herbal Products Assn; 2002.
Warnecke G. Psychosomatic dysfunctions in the female climacteric: clinical
effectiveness and tolerance of kava extract WS 1490 [in German]. Fortsch Med 1991;109(4):119–22.
Warnecke G, Pfaender H, Gerster G, Gracza E. Efficacy of an extract of
Kavaroot in patients with climacteric syndrome [in German]. Zeitschrift für Phytotherapie
1990;11:81–6.
Watkins LL, Connor KM, Davidson JRT. Effect of kava extract on vagal
cardiac control in generalized anxiety disorder: preliminary findings. J Psychopharmacol 2001;15(4):283–6.
Wheatley D. Kava and valerian in the treatment of stress-induced insomnia. Phytother Res 2001;15(6):549–51.
Woelk H, Kapoula O, Lehrl S, Schröter K, Weinholz P. A comparison of kava
special extract WS 1490 and benzodiazepines in patients with anxiety. Z Allg Med 1993;69:271–7.
Woodfield R. Safety of Kava-kava products—temporary and voluntary
suspension of sale and supply [letter]. London, U.K.: Medicines Control Agency;
2001 Dec 19.
World Health Organization (WHO). Regulatory
Status of Herbal Medicines: A Worldwide Review. Geneva, Switzerland: World
Health Organization Traditional Medicine Programme; 1998. p. 8–9.
Worth T. TGA recalls over the counter medicines containing kava [press
release]. 2002 Aug 15.